Good morning, and welcome to the 2026 Annual Meeting of Stockholders of Rallybio Corporation. I am Martin Mackay, Chairman of Rallybio. For the convenience of our stockholders, we are hosting this annual meeting virtually. It is my pleasure to welcome you and to thank you for joining us today. Stockholders can access a copy of the agenda and the rules of procedure for today's meeting via the web portal for this meeting. You may ask questions regarding the proposals being voted on at this meeting and in accordance with these rules. Please submit pertinent questions via the web portal. Questions will be answered prior to the opening of the polls. Although we may not be able to answer every question, we will do our best to provide a response to as many as possible. Please be aware that only stockholders of record on September 11, 2026, who entered the meeting using their unique control number, will be able to ask questions and vote in today's meeting. It is now 10:00 A.M. Eastern Time on November 4, 2026, and this meeting is officially called to order. I would like to introduce the other members of the board attending our virtual meeting today. Helen Boudreau has served as one of our Directors since September 2020. Wendy Chung since August 2022. Rob Hopfner since March 2020. Ron Hunt has served as one of our Directors since 2018. Lucian Iancovici since May 2020. Hui Liu since April 2022. Christine Nash also since April 2022. Paula Soteropoulos since October 2020. Steve Uden has served as our Director since August 2023 and also serves as our Chief Executive Officer and President. Now it is my pleasure to introduce Rallybio's Chief Financial Officer, John Lieber, who will act as Secretary of the meeting. I will turn to him with any procedural issues that may arise. John. Thank you, Martin. We are also joined here today by our independent auditors, Deloitte & Touche LLP. Finally, the company has appointed Broadridge Financial Solutions to act as Inspector of Elections. Marlene Aguilar from Broadridge is with us today and has taken the oath of Inspector of Elections. The Board of Directors fixed September 11, 2026, as the record date for determining stockholders entitled to vote at this meeting. An affidavit of Broadridge has been delivered attesting to the fact that, one, the notice of the meeting, two, the proxy statement, and three, the 2026 annual report to stockholders were mailed to all stockholders as of the record date commencing on or about October 15, 2026. The stockholder list shows that as of the record date, there were 5,312,584 shares of common stock outstanding and entitled to vote at this meeting. We are informed by the Inspector of Elections that there are represented virtually or by proxy shares of common stock representing 4,790,320 votes, or approximately 90% of the voting power on the record date. Since this represents more than a majority of the shares of common stock entitled to vote at this annual meeting, a quorum is present for purposes of transacting business. Now I will present the matters to be voted upon. Please note that we will give stockholders an opportunity to comment on the proposals themselves after all proposals have been presented and before the polls open. Rallybio has not received notice from any of its stockholders as required under its amended and restated bylaws of any other matter to be considered at today's annual meeting, and therefore, no other proposals may be properly introduced by stockholders. Proposal one is to approve the issuance of shares of Rallybio's common stock to the security holders of Avenzo Therapeutics Inc., pursuant to the terms of the agreement and plan of merger and reorganization dated as of May 31, 2026, by and among Rallybio Corporation, Avenzo Therapeutics Inc., and Farmington Merger Sub, Inc., which will, A, represent more than 20% of the shares of Rallybio's common stock outstanding immediately prior to the merger of Farmington Sub with and into Avenzo, and B, result in a change of control of Rallybio Corporation pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) respectively. Proposal two is to approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio in the range of one for two to one for nine inclusive, with the final ratio to be mutually determined by Rallybio and Avenzo. Proposal three is to approve an amendment to our amended and restated certificate of incorporation to change the name of Rallybio Corporation to Avenzo Therapeutics Inc. Proposal four is to approve an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of our common stock from 200 million shares to 500 million shares. Proposal five is the election of class 2 directors to hold office until the 2029 annual meeting of stockholders and until such person's successor is duly elected and qualified in accordance with our amended and restated certificate of incorporation, or until such person's earlier death, disqualification, resignation, or removal. The following four people have been nominated by the board: Viva Newton, Helen Boudreau, Lucian Iancovici, and Christine Nash. Proposal six is to ratify the appointment of Deloitte & Touche LLP as Rallybio Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2026. Proposal seven is to approve the Avenzo Therapeutics Inc. 2026 Equity Incentive Plan, which would become effective on the date immediately following the consummation of the merger and is contingent upon the completion of the merger. Proposal eight is to approve the Avenzo Therapeutics Inc. 2026 Employee Stock Purchase Plan, which would become effective on the date immediately following the consummation of the merger and is contingent on the completion of the merger. Proposal nine is to approve an adjournment of Rallybio Corporation 2026 Annual Meeting of Stockholders if necessary to solicit additional proxies if there are not sufficient votes in favor of proposal one, proposal two, proposal three, and proposal four. If any stockholder would like to make a comment or ask a question regarding either of the proposals or voting procedures, please submit your question through the web portal. Being no questions, thank you very much. We will now proceed with voting. It is 10:07 A.M. Eastern Time on November 4th, 2026, and the polls are now open. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. That completes the voting on proposals before the stockholders, and I now declare the polls for the meeting closed. We have been informed by the Inspector of Elections that the preliminary vote report shows that the issuance of shares of our common stock to security holders of Avenzo Therapeutics, the reverse stock split of our common stock, the amendments to our amended and restated certificate of incorporation, and the Avenzo Therapeutics 2026 Equity Incentive Plan and Employee Stock Purchase Plan have been approved, that the nominees for election to the board have been duly elected, and the appointment of Deloitte & Touche LLP as Rallybio's independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been ratified. We will be reporting the final results in a Form 8-K to be filed within four business days. With that, I turn the meeting back over to Martin Mackay, the Chair of the Board. Thank you, John. There being no further business to come before the meeting, the 2026 Annual Meeting of Stockholders of Rallybio Corporation is now adjourned. On behalf of the company, board, and members of management, I would like to express my sincere appreciation to the stockholders who attended this meeting. That concludes our meeting today. You may now disconnect.